← Back to Home

Caribou Plans to Halt Development of Two Allogeneic CAR-T Therapies, Launches Review of Strategic Alternatives

Funding requirements are putting the brakes on cell therapy development. Caribou will substantially reduce its workforce and wind down two early-stage trials while pursuing a merger, acquisition or asset transaction; long-term follow-up of patients already treated will continue.

By SURL BioNews

Moving cell therapies from early-stage trials into larger-scale testing requires more than scientific progress—it also requires sufficient funding to support further development. CRISPR gene-editing company Caribou Biosciences announced on October 6, 2026, that it plans to discontinue further development of two allogeneic CAR-T cell therapies and evaluate mergers, acquisitions and other strategic transactions involving the company or its assets.

Implementation of this shift is already underway. According to an 8-K filing with the U.S. Securities and Exchange Commission, the board approved a restructuring on October 2 and established a transaction committee. The company will substantially reduce its workforce, with most affected employees expected to leave in the fourth quarter. Only a small number of staff will remain to support transaction execution and the wind-down of operations.

The two programs are vispa-cel for relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. Both are allogeneic CAR-T therapies based on donor-derived T cells engineered to recognize cancer cells. The development goal for this type of therapy is to potentially free cell therapy from the constraints of manufacturing treatments individually for each patient.

Caribou attributed the decision primarily to the financing environment for allogeneic CAR-T therapies, saying that securing sufficient capital to advance the programs has become increasingly difficult. The company said it had reached agreement with the U.S. Food and Drug Administration on the design of a Phase 3 trial for vispa-cel. However, agreement on a trial design does not mean that efficacy has been confirmed or that a product has been approved for marketing. The announcement also provided no new clinical data, so it cannot serve as a basis for assessing the ultimate benefits and risks of the two therapies.

Discontinuing development still entails ongoing responsibilities and expenses. The company estimates total restructuring costs of $15 million to $19 million, including $10 million to $11 million for severance, continued healthcare coverage and related costs, and another $5 million to $8 million to wind down the ANTLER and CaMMouflage Phase 1 trials. Long-term follow-up studies of patients previously treated with the investigational products remain ongoing.

These amounts do not cover all potential expenses. Caribou also intends to terminate applicable contracts, address intellectual property licensing arrangements, and seek to sublease facilities or terminate leases. Related lease, contract termination and asset impairment expenses could not be reasonably estimated at the time of the filing. The announced restructuring budget is therefore not a definitive final total.

Wedbush Securities is serving as the exclusive financial adviser for the transaction review. There is currently no deadline for completion, and no confirmed buyer or transaction agreement has been announced. For the two therapies, what is certain for now is that Caribou will stop investing in further development. Whether the programs can continue through a transaction remains dependent on arrangements that have yet to be finalized.

References

  1. The Manila Times
  2. U.S. Securities and Exchange Commission